Close Menu

NEW YORK – Geneos Therapeutics said Wednesday that its personalized vaccine GNOS-PV02 will be used in an upcoming clinical trial for advanced hepatocellular carcinoma patients who have progressed on or are intolerant to first-line treatment with a tyrosine kinase inhibitor.

The vaccine contains patient-specific neoantigen targets that will be identified through tumor sequencing. The company's GT-EPIC platform will be used to develop the personalized DNA-based therapies tailored to each patient's unique tumor mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.